StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Sarepta Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Sarepta Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.97B, down 20.4% year over year. For fiscal 2025 it was $2.20B, up 15.6% from the year before. Over ten years it grew 111.1% a year on average. The highest annual figure on record is $2.20B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.20B+15.6%
FY2024Dec 31, 2024$1.90B+53.0%
FY2023Dec 31, 2023$1.24B+33.3%
FY2022Dec 31, 2022$933.01M+32.9%
FY2021Dec 31, 2021$701.89M+30.0%
FY2020Dec 31, 2020$540.10M+41.8%
FY2019Dec 31, 2019$380.83M+26.5%
FY2018Dec 31, 2018$301.03M+94.7%
FY2017Dec 31, 2017$154.58M+2751.6%
FY2016Dec 31, 2016$5.42M+332.6%
FY2015Dec 31, 2015$1.25M-87.2%
FY2014Dec 31, 2014$9.76M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$401.25M-34.3%
Q1 FY2026Mar 31, 2026$730.80M-1.9%
Q4 FY2025Dec 31, 2025$442.93M-32.7%
Q3 FY2025Sep 30, 2025$399.36M-14.5%
Q2 FY2025Jun 30, 2025$611.09M+68.4%
Q1 FY2025Mar 31, 2025$744.86M+80.2%
Q4 FY2024Dec 31, 2024$658.41M+65.9%
Q3 FY2024Sep 30, 2024$467.17M+40.8%
Q2 FY2024Jun 30, 2024$362.93M+38.9%
Q1 FY2024Mar 31, 2024$413.46M+63.1%
Q4 FY2023Dec 31, 2023$396.78M+53.5%
Q3 FY2023Sep 30, 2023$331.82M+44.1%
Q2 FY2023Jun 30, 2023$261.24M+11.9%
Q1 FY2023Mar 31, 2023$253.50M+20.2%
Q4 FY2022Dec 31, 2022$258.43M+28.3%
Q3 FY2022Sep 30, 2022$230.27M+21.6%
Q2 FY2022Jun 30, 2022$233.49M+42.3%
Q1 FY2022Mar 31, 2022$210.83M+43.5%
Q4 FY2021Dec 31, 2021$201.46M+38.8%
Q3 FY2021Sep 30, 2021$189.41M+31.6%
Q2 FY2021Jun 30, 2021$164.09M+19.5%
Q1 FY2021Mar 31, 2021$146.93M+29.3%
Q4 FY2020Dec 31, 2020$145.14M+45.0%
Q3 FY2020Sep 30, 2020$143.92M+45.3%
Q2 FY2020Jun 30, 2020$137.36M+45.1%
Q1 FY2020Mar 31, 2020$113.67M+30.6%
Q4 FY2019Dec 31, 2019$100.11M+18.6%
Q3 FY2019Sep 30, 2019$99.04M+26.2%
Q2 FY2019Jun 30, 2019$94.67M+28.7%
Q1 FY2019Mar 31, 2019$87.01M+34.7%
Q4 FY2018Dec 31, 2018$84.42M+47.4%
Q3 FY2018Sep 30, 2018$78.49M+70.8%
Q2 FY2018Jun 30, 2018$73.53M+110.0%
Q1 FY2018Mar 31, 2018$64.60M+295.3%
Q4 FY2017Dec 31, 2017$57.28M+956.6%
Q3 FY2017Sep 30, 2017$45.95M–
Q2 FY2017Jun 30, 2017$35.01M–
Q1 FY2017Mar 31, 2017$16.34M–
Q4 FY2016Dec 31, 2016$5.42M–

More Sarepta Therapeutics figures

See a number that looks wrong?